The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
Abstract
BACKGROUND: Persons with mixed hyperlipidemia are at risk for atherosclerotic cardiovascular disease due to an elevated non-high-density lipoprotein (HDL) cholesterol level, which is driven by remnant cholesterol in triglyceride-rich lipoproteins. The metabolism and clearance of triglyceride-rich lipoproteins are down-regulated through apolipoprotein C3 (APOC3)-mediated inhibition of lipoprotein lipase. METHODS: We carried out a 48-week, phase 2b, double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of plozasiran, a hepatocyte-targeted APOC3 small interfering RNA, in patients with mixed hyperlipidemia (i.e., a triglyceride level of 150 to 499 mg per deciliter and either a low-density lipoprotein [LDL] cholesterol level of ≥70 mg per deciliter or a non-HDL cholesterol level of ≥100 mg per deciliter). The participants were assigned in a 3:1 ratio to receive plozasiran or placebo within each of four cohorts. In the first three cohorts, the participants received a subcutaneous injection of plozasiran (10 mg, 25 mg, or 50 mg) or placebo on day 1 and at week 12 (quarterly doses). In the fourth cohort, participants received 50 mg of plozasiran or placebo on day 1 and at week 24 (half-yearly dose). The data from the participants who received placebo were pooled. The primary end point was the percent change in fasting triglyceride level at week 24. RESULTS: A total of 353 participants underwent randomization. At week 24, significant reductions in the fasting triglyceride level were observed with plozasiran, with differences, as compared with placebo, in the least-squares mean percent change from baseline of -49.8 percentage points (95% confidence interval [CI], -59.0 to -40.6) with the 10-mg-quarterly dose, -56.0 percentage points (95% CI, -65.1 to -46.8) with the 25-mg-quarterly dose, -62.4 percentage points (95% CI, -71.5 to -53.2) with the 50-mg-quarterly dose, and -44.2 percentage points (95% CI, -53.4 to -35.0) with the 50-mg-half-yearly dose (P<0.001 for all comparisons). Worsening glycemic control was observed in 10% of the participants receiving placebo, 12% of those receiving the 10-mg-quarterly dose, 7% of those receiving the 25-mg-quarterly dose, 20% of those receiving the 50-mg-quarterly dose, and 21% of those receiving the 50-mg-half-yearly dose. CONCLUSIONS: In this randomized, controlled trial involving participants with mixed hyperlipidemia, plozasiran, as compared with placebo, significantly reduced triglyceride levels at 24 weeks. A clinical outcomes trial is warranted. (Funded by Arrowhead Pharmaceuticals; MUIR ClinicalTrials.gov number NCT04998201.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mild elevations in aminotransferase levels as well as small increases in glycated hemoglobin levels have also been seen with plozasiran 18,23,29 and are similar to the now well-established safety profile of statins. 30,31”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [23]
In the citing paper
“In MUIR [119] and SHASTA-2 [120], plozasiran similarly reduced TG by 50–60% and improved remnant cholesterol, non–HDL-C, and apoB, while modest, dose-dependent LDL-C increases were observed at higher doses.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [119]
In the citing paper
“Ultimately, four RCTs met al.l eligibility criteria and were included in the final analysis [16, 17, 22, 23].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [16]
In the citing paper
“The meta-analysis included data from 4 clinical trials [16, 17, 22, 23], encompassing a total of 1,514 participants—534 assigned to various doses and treatment durations of plozasiran, and 980 receiving placebo.”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [16]
In the citing paper
“At 24 weeks, the analysis showed significant heterogeneity (P = 0.02, I² = 60%), which was resolved by excluding the study by Ballantyne et al. (2024) [16] (50 mg, H) (P = 0.15, I² = 38%).”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [16]
In the citing paper
“which was resolved after excluding Ballantyne et al., 2024 [16] (50 mg, H) (P = 0.35, I² = 10%)”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [16]
In the citing paper
“which was resolved by excluding Ballantyne et al., 2024 [16] (50 mg, Q) (P = 0.35, I² = 10%)”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [16]
In the citing paper
“Concerning safety findings for plozasiran, we observed slight increases in HbA1c, AST, and ALT levels, along with a higher incidence of headaches.”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [16]
In the citing paper
“Moreover, the rises seen in liver transaminases were considered non-serious and associated with higher and more frequent doses of plozasiran, which trials mitigated by changing dosing and frequency [16, 22].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [16]
In the citing paper
“Moreover, the rises seen in liver transaminases were considered non-serious and associated with higher and more frequent doses of plozasiran, which trials mitigated by changing dosing and frequency [16, 22].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [16]
In the citing paper
“Ballantyne et al. (2024) included patients with mixed dyslipidemia to explore whether plozasiran’s lipid-lowering effects could extend to individuals at risk for ASCVD and support the rationale for a dedicated cardiovascular outcomes trial [16].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [16]
In the citing paper
“Subgroup analyses confirmed that changes in HbA1c, ALT, and AST levels were dose- and regimen-dependent.”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [16]
Citations
Cites
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Flagged first, then by citations
Research works printed but not linked: 1
- Jacobsen A Duffy E Blumenthal RS Martin SS. Clinical review on triglycerides. Washington DC: American College of Cardiology March 4 2020 (https://www.acc.org/Latest-in-Cardiology/Articles/2020/03/03/15/08/Clinical-Review-on-Triglycerides).
Cited by
Sorted by citations
Items 101–200 of 215
Small interfering RNA (siRNA) in dyslipidemia: a systematic review on safety and efficacy of siRNA
Alla, S. S. M., Shah, D. J., Meyur, S., Agarwal, P., Alla, D., Moraboina, S. L., Ghadvaje, G. V., Bayeh, R. G., Malireddi, A., Shajan, T., et al. (2025) · Journal of Experimental Pharmacology · doi:10.2147/jep.s521579 · Cited by 4
Tang, X. L., Hooper, A. J., & Burnett, J. R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2414126 · Cited by 4
Olezarsen and Plozasiran in Dyslipidemia Management: A Narrative Review of Clinical Trials
Olatunji, G. D., Ogieuhi, I. J., Kokori, E., Ajekiigbe, V. O., Ajimotokan, O. I., Odukudu, G.-D. O., Owolabi, S., Anyacho, S., Nwakama, C., Babalola, A. E., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00677-7 · Cited by 4
Diagnosis, Evaluation, and Management of Severe Hypertriglyceridemia
Krishnamurthy, A., Homan, E. A., & Kim, S. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00758-9 · Cited by 4
Watts, G. F., & Chan, D. C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae931 · Cited by 4
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors
Mansoor, T., Nambi, V., Parikh, S. S., Misra, A., Ismayl, M., Sullivan, C., Sperling, L. S., Virani, S. S., Rifai, M. A., Koshy, S. K. G., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00748-7 · Cited by 4
Hvid, K., Balling, M., Nordestgaard, B. G., & Afzal, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf735 · Cited by 4
Nucleic Acid–Based Therapies — The Next Frontier in Treating Dyslipidemias
Hegele, R. A. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.01.026 · Cited by 4
Triglyceride reduction after MI and major adverse outcomes in SWEDEHEART—insights for future trials
Schubert, J. R., Hagström, E., Westerbergh, J., Leósdóttir, M., & Ray, K. K. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag076 · Cited by 4
Loomba, R. S., de‐Madaria, E., Afghani, E., Singh, V. K., & Leeper, N. J. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70623 · Cited by 4
Self-citationWadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120772 · Cited by 4
Pan, Z., Zaman, M. A., Kalsoom, S., & Zhang, Y. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2423724 · Cited by 4
Santos, R. D., Ray, K. K., Bacquer, D. D., Jennings, C. S., Kotseva, K., Rydén, L., Lip, G. Y. H., Erlund, I., Ganly, S., Vihervaara, T., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119215 · Cited by 4
Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease
Natarajan, P. (2024) · New England Journal of Medicine · doi:10.1056/nejme2405647 · Cited by 4
Brown, S., Malinowska, A. L., Bennett, M., Correa-Sánchez, A. F., Valencia, L. L. H., Lucignoli, A. P., Barton, A. K., Clark, L., Sluimer, J. C., Webster, S. P., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101364 · Cited by 4
Apolipoprotein C3 Promotes Angiogenesis in an Inflammatory Mouse Model of Peripheral Artery Disease
Thomas, J., Bamhare, P. M., Mulangala, J., Bursill, C. A., Nicholls, S. J., Bartolo, B. A. D., & Bubb, K. J. (2025) · The FASEB Journal · doi:10.1096/fj.202502155r · Cited by 3
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D. A., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 4
Zhou, Z., Chen, J., Wang, H., Han, Y., Liu, C., Shen, Q., Dong, Z., Lu, K., Zhai, C., Xu, Y., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104088 · Cited by 3
Ballantyne, C. M., Baass, A. W., Rosenson, R. S., Hegele, R. A., Nicholls, S. J., Vasas, S., Clifton, P. M., Lucas, K. J., Páll, D., Zhou, R., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101523 · Cited by 3
Self-citationWatts, G. F., Scott, R., Sullivan, D., BAKER, J., Clifton, P. M., Hamilton, J., Given, B. D., Melquist, S., Zhou, R., Gaudet, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04307-8 · Cited by 3
Self-citationLipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins
Brandts, J., Verket, M., Zambon, A., Marx, N., Müller-Wieland, D., & Federici, M. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03166-4 · Cited by 3
The Year in Cardiovascular Medicine 2024: the top 10 papers in dyslipidaemias
Tokgözoğlu, L. S., Orringer, C. E., & Catapano, A. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf077 · Cited by 3
Safety and Efficacy of Novel Agents: Pelacarsen, Obicetrapib, and Beyond
Palimkar, P., Satish, P., Rajendran, R. J., Rath, H. M., & Sharma, R. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_66_2025 · Cited by 3
RNA interference lowers triglyceride levels
Lim, G. B. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01052-8 · Cited by 2
Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent
Marston, N., & Zimerman, A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001013 · Cited by 3
D’Erasmo, L., Tramontano, D., & Arca, M. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000941 · Cited by 2
Larouche, M., Brisson, D., Roy, N., Grenon, C., Poirier, P., Muhsin, M., & Gaudet, D. (2025) · JIMD Reports · doi:10.1002/jmd2.70052 · Cited by 2
Self-citationKatzmann, J. L., & Laufs, U. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01390-7 · Cited by 2
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
Nordestgaard, A. G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01393-4 · Cited by 2
Zhang, X., Ren, Q., Guo, X., Chen, Y., Sun, S., Wang, M., Ren, X., Liu, C., & Mengqi, Z. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121473 · Cited by 2
ApoC-III inhibition: from regulatory approval to equitable implementation
Gaudet, D., Larouche, M., & Stroes, E. S. G. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01281-z · Cited by 2
Self-citationEmara, A., Mansour, A., Aboeldahab, H. A., Awashra, A., Abbas, O. F., Abdul‐Hafez, H. A., Alsubaiei, A. A., AlSejari, N., Saif, H. S., Shubietah, A. R. M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70716 · Cited by 2
Zadeh, S. S. T., Toth, P. P., & Banach, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789019 · Cited by 2
New drugs approved by the FDA in 2025: Synthesis and clinical applications
Liu, W., Li, X., Han, Y., Wu, L., Wang, M., Xuan, W., Xu, Z., Liu, W., Zhao, Q., & Hao, S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118952 · Cited by 2
Remnant cholesterol — The transition from biomarker to risk factor
Rosenson, R. S., Velamuri, D. N., Muntner, P., & Goonewardena, S. N. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120755 · Cited by 3
Self-citationPilsgaard, F., Emanuelsson, F., Vedel‐Krogh, S., Nordestgaard, B. G., & Kobylecki, C. J. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120798 · Cited by 3
Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease
Davidson, N. O. (2026) · Circulation Research · doi:10.1161/circresaha.126.327269 · Cited by 2
ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome
Yin, E. B., Wanat, M. A., & Wang, E. M. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261452675 · Cited by 2
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Ahmad, M., & Hegele, R. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00768-0 · Cited by 4
Pechetty, R., Rao, P. S., Deb, T., Shekar, C., & Deepthi, K. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_55_2025 · Cited by 2
Elbahloul, M. A., Gamal, A., Maihoub, O., Elbaz Hassan, M. M., Attia, M. K., Salah, A. M., Elboraay, T., Awad, A. K., Akoum, A., Elazab, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70717 · Cited by 1
Novel agents for treating severe hypertriglyceridemia
Wierzbicki, A. S. (2024) · Med · doi:10.1016/j.medj.2024.10.019 · Cited by 1
Funabashi, S., Kataoka, Y., Nicholls, S. J., Kitahara, S., Makino, H., Matsubara, M., Matsuo, M., Omura‐Ohata, Y., Koezuka, R., Tochiya, M., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.204 · Cited by 1
Pediatric Hypertriglyceridemia: Lipoprotein Metabolism, Etiology, and Management
Moriyama, H., & Ham, J. N. (2025) · Current Pediatrics Reports · doi:10.1007/s40124-025-00349-7 · Cited by 2
Larouche, M., Ballantyne, C. M., Dufour, J., Brisson, D., Given, B. D., & Gaudet, D. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf146 · Cited by 1
Self-citationMai, W., Jiao, Y., & Deng, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-10879-1 · Cited by 1
Pei, X., Dong, W., Yu, Y., Wang, Y., Wang, H., & Dai, L. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1689778 · Cited by 1
Hypertriglyceridaemia and elevated cardiovascular risk: will ANGPTL4 inhibition address both?
Katzmann, J. L., & Laufs, U. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf250 · Cited by 1
A Year in Coronary Artery Disease: A Focussed 2024 Update
Swinn, T., O’Shea, D., & Dastidar, A. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2025.0297 · Cited by 1
VLDL cholesterol and ASCVD risk: A population-based study
Balling, M., Roepstorff, O. G., Gerds, T. A., Varbo, A., Langsted, A., Mortensen, M. B., Smith, G. D., Nordestgaard, B. G., & Afzal, S. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.024 · Cited by 1
Meghashree, N., B, K. C., & Shivaraj, D. R. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.72 · Cited by 1
RNA interference for lipid disorders: is this the future?
Nassif, M., Fazoli, R. T., & Generoso, G. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001033 · Cited by 1
Gangopadhyay, S., Sharma, S. N., Das, G., Ghosh, A., Dilnawaj, Y., Mukherjee, M., Sinha, S., & Gore, K. R. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118614 · Cited by 1
The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome
Hang, S., & Hegele, R. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2646166 · Cited by 2
Fadah, K., Alomari, M., Elchouemi, M., & Lange, R. A. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02362-8 · Cited by 2
Current and Emerging Pharmacological Therapies for Hypertriglyceridemia
Alhomoud, I. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083573 · Cited by 2
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
Ousey, J. A., Gosselin, N. H., Ta, A., & Shi, J. G. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70190 · Cited by 1
RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside
Ali, I., Qiu, J., Cheang, W. S., Wang, G., & Xu, S. (2026) · Research · doi:10.34133/research.1288 · Cited by 1
Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study
Chen, Z., Triatin, R. D., Luo, L., Snieder, H., Schmidt, A. F., Ditmarsch, M., Kastelein, J. J. P., Dullaart, R. P. F., Kuivenhoven, J. A., & Thio, C. H. L. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03209-w · Cited by 1
Emergent RNA targets in cardiovascular disease: likely candidates for treatment development
Barbi, V., Romeo, M. A., Zamperla, M. G., Favretto, F., Atlante, S., Lucotti, A., Gaetano, C., & Martelli, F. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671679 · Cited by 1
Zhang, Y., Li, S. Q., Xu, S., Zhao, R., zheng, F., & Wu, J. (2026) · Bioscience Reports · doi:10.1042/bsr20260258 · Cited by 1
Current landscape of RNA chemistry and delivery in cancer immunotherapy
Tobias, H., Porter, S., Marcelo, I., Koons, A., Spina, S. C., Culkins, C., & Kimmel, B. R. (2026) · RSC Chemical Biology · doi:10.1039/d6cb00037a · Cited by 1
siRNAs targeting ANGPTL3 for mixed dyslipidemia
Gouni‐Berthold, I. (2025) · Med · doi:10.1016/j.medj.2025.100746 · Cited by 1
Plozasiran and Apolipoprotein C-III Inhibition
Schwartz, G. G., & Cobbaert, C. M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.519 · Cited by 1
Angiopoietin-Like Protein 3 Inhibition
Stroes, E. S. G., Weijs, B. M., & Annink, M. E. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.514 · Cited by 1
Bench to all Bedsides in Genomics and Precision Medicine
Tcheandjieu, C., Robinson, C., & Natarajan, P. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039202 · Cited by 1
Remnant cholesterol: a promising target besides LDL-C for cardiovascular risk reduction?
Valéro, R., Gallo, A., & Béliard, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf506 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
Widjaja, J. S., Adji, A. S., Baraja, A., Dharmasaputra, A., Rosyadi, R. N., Komalasari, I., Mustofa, A., Multazam, C. E. C. Z., Alkaff, F. F., & Saputra, P. B. T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179420
Research Progress on Residual Cholesterol and Cardiovascular Disease Risk
唐, 安. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123209
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Tomlinson, B., & Chan, P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451752
Sobral, M. V. S., Queiroz, I., dos Santos, J. P. P., Pirolla, R. D. C., Martins, D. C., Silva, G., da Silva, D. P., Assakawa, C., Vilela, T. A. A., Filho, M. A. G., et al. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001875
Leveraging drug-target Mendelian randomization for tailored lipoprotein-lipid lowering
Gagnon, É., & Arsenault, B. J. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000977
Outland, E. H., Xin, Y., Dickson, A. L., Mundo, S., Tao, R., Zhong, X. Y., Karakoc, G., Serley, S., Jiang, L., Cox, N. J., et al. (2025) · medRxiv · doi:10.1101/2025.03.07.25323588
Loss-of-Function in APOC3 and Protection Against Aortic Valve Disease
Bourgault, J., Wulff, A. B., Houessou, U., Manikpurage, H. D., Clavel, M.-A. A., Pîbarot, P., Bossé, Y., Mathieu, P., Tybjærg‐Hansen, A., Thériault, S., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.028
The next step in cardiovascular risk reduction: targeting remnant cholesterol
Parhofer, K. G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf315
He, K., Ku, X., Chen, Z., Wu, C., Liao, C., Li, L., Qu, H., Hong, P., Bai, S., Cui, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.24.678175
Where is the treatment of atherosclerosis heading?
Mayer, O. (2025) · Medicína pro praxi · doi:10.36290/med.2025.050
Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trials
Hooper, A. J., Parameswaran, T., & Burnett, J. R. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2571213
The Crosstalk Between Non-Coding RNAs and Lipid Metabolism in Chronic Disease Progression
Zayani, Z., Matinahmadi, A., Tavakolpournegari, A., Moosavi, S. S., & Bidooki, S. H. (2025) · Lipidology · doi:10.3390/lipidology2040019
Olezarsen in moderate hypertriglyceridemia: The Essence-TIMI 73b trial
Gouni‐Berthold, I. (2025) · Med · doi:10.1016/j.medj.2025.100923
Genetic instruments and drug prediction: will APOC3 silencing reduce cardiovascular end points?
Hegele, R. A. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag018
Fujioka, Y., Tanaka, S.-I., Tsujino, T., Ishida, T., & Hirata, K. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66073
A year in pharmacology: new drugs approved by the US food and drug administration in 2025
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05193-0
A CSGNN model-based method for essential protein identification
Li, Z., Yu, Z., & Li, P. (2026) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2026.1731178
Burhan, M., Ibrahim, T., Naveed, M. A., Ansari, Z., Ansab, M., Fatima, K., Ashraf, S., Shahid, Z. U. A., Raza, A., & Raza, S. H. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.052
Tong, B., Wang, J., Chen, J., Zhang, Q., Xu, Z., Yang, K., & Chen, X. (2026) · Experimental Biology and Medicine · doi:10.3389/ebm.2026.10827
Clinical identification of familial chylomicronemia syndrome and novel therapeutic options
Hang, S., & Hegele, R. A. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2661212
Emara, A., Awashra, A., Aboeldahab, H. A., Gadelmawla, A. F., Abdul‐Hafez, H. A., Alharran, A. M., Alsubaiei, A. A., AlRumaihi, M. J., Albuhmaid, S. A., & Shubietah, A. R. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70220
Remnant cholesterol reduction for reduction of residual ASCVD risk
Doi, T., Hvid, K., & Nordestgaard, B. G. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag063
Li, R., Li, Y. H., Zhang, C. Y., Liu, H., Jiang, J., Yao, D., & Wei, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178917
Lipid-related cardiovascular risk beyond low-density lipoprotein cholesterol
Balling, M., Hvid, K., Varbo, A., Langsted, A., Nordestgaard, B. G., & Afzal, S. (2026) · Heart · doi:10.1136/heartjnl-2025-326404
Mourre, F., & Béliard, S. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.05.002
Clinical Pharmacology of Plozasiran
Huston, J., Orey, D., Corona, K., Ashchi, A., Ashchi, A., Deeb, E., Deeb, A., Rouhbakhsh, R., Berner, J., Sutton, D., et al. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00808-6
Kassem, B. A., Shaik, F. A., Sorour, O., Abdelhamid, A. H., Fazal, A., Dakroub, A. H., & Eid, A. H. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001846
Translational Nanomedicine and Delivery Tools for Cardiovascular Disease Therapy and Diagnostics
Miller, M. A., & Williams, R. M. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-22285-5_10
Ahn, C., Jeong, H., Yim, H. W., Kim, N. J., Han, S., & Oh, I. (2026) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2026.1855572
Björnson, E., & Adiels, M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01442-y
Treatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Self-citation
Metadata
- Authors
- Ballantyne, C. M., Vasas, S., Azizad, M., Clifton, P., Rosenson, R. S., Chang, T., Melquist, S., Zhou, R., Mushin, M., Leeper, N. J., Hellawell, J., & Gaudet, D.
- Affiliations
- Royal Adelaide Hospital (AU)
- From the Baylor College of Medicine and the Texas Heart Institute, Houston (C.M.B.); Borbánya Praxis, Nyíregyháza, Hungary (S.V.); Valley Clinical Trials, Northridge (M.A.), Arrowhead Pharmaceuticals, Pasadena (T.C., S.M., R.Z., M.M., J.H.), and the Stanford School of Medicine, Stanford (N.J.L.) — all in California; the Royal Adelaide Hospital, Adelaide, SA, Australia (P.C.); the Icahn School of Medicine at Mount Sinai, New York (R.S.R.); and the Department of Medicine, Université de Montréal and Ecogene-21, Quebec, QC, Canada (D.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-09-12
- Volume
- 391
- Issue
- 10
- Pages
- 899-912
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399087766
- Semantic Scholar
- c67a77a19492dfb8d4608c1ccc2c06e5e7c68abe
- Cited by
- 210
- References
- 44
- Citations by year
- 2026: 73 · 2025: 106 · 2024: 30
- FWCI
- 55.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Arrowhead Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- plozasiran, apolipoprotein C-III, siRNA, mixed dyslipidemia, triglyceride-rich lipoproteins, remnant cholesterol, non-HDL cholesterol, lipoprotein lipase inhibition, triglyceride lowering, atherosclerotic cardiovascular disease, dose comparison, safety and tolerability, subcutaneous injection
- MeSH terms
- RNAi Therapeutics, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Hyperlipidemias, Cholesterol, LDL, Male, Middle Aged, Triglycerides, RNA, Small Interfering, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
